These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30265861)

  • 1. The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells.
    Puli OR; Danysh BP; McBeath E; Sinha DK; Hoang NM; Powell RT; Danysh HE; Cabanillas ME; Cote GJ; Hofmann MC
    Neoplasia; 2018 Nov; 20(11):1121-1134. PubMed ID: 30265861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
    Song YS; Yoo SK; Kim HH; Jung G; Oh AR; Cha JY; Kim SJ; Cho SW; Lee KE; Seo JS; Park YJ
    Endocr Relat Cancer; 2019 Jun; 26(6):629-641. PubMed ID: 30999281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF
    Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y
    J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphenol A at a human exposed level can promote epithelial-mesenchymal transition in papillary thyroid carcinoma harbouring BRAF
    Li L; Li H; Zhang J; Gao X; Jin H; Liu R; Zhang Z; Zhang X; Wang X; Qu P; Zhao Y; Lu X
    J Cell Mol Med; 2021 Feb; 25(3):1739-1749. PubMed ID: 33469997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Toll-like Receptor 4 Overexpression in Papillary Thyroid Cancer by MAPK/ERK-Induced ETS1 Transcriptional Activity.
    Peyret V; Nazar M; Martín M; Quintar AA; Fernandez EA; Geysels RC; Fuziwara CS; Montesinos MM; Maldonado CA; Santisteban P; Kimura ET; Pellizas CG; Nicola JP; Masini-Repiso AM
    Mol Cancer Res; 2018 May; 16(5):833-845. PubMed ID: 29523762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.
    Chen H; Chen W; Zhang X; Hu L; Tang G; Kong J; Wang Z
    Oncol Rep; 2019 Jan; 41(1):570-578. PubMed ID: 30365150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-200b/c-RAP1B axis represses tumorigenesis and malignant progression of papillary thyroid carcinoma through inhibiting the NF-κB/Twist1 pathway.
    Zhou B; Xu J; Chen Y; Gao S; Feng X; Lu X
    Exp Cell Res; 2020 Feb; 387(2):111785. PubMed ID: 31877303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
    Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
    Pinheiro Dos Santos MJC; Bastos AU; da Costa VR; Delcelo R; Lindsey SC; Colozza-Gama GA; Peng H; Rauscher FJ; Oler G; Cerutti JM
    Endocr Pathol; 2018 Sep; 29(3):222-230. PubMed ID: 29560564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ETS Factor ETV5 Activates the Mutant Telomerase Reverse Transcriptase Promoter in Thyroid Cancer.
    Bullock M; Lim G; Zhu Y; Åberg H; Kurdyukov S; Clifton-Bligh R
    Thyroid; 2019 Nov; 29(11):1623-1633. PubMed ID: 31452441
    [No Abstract]   [Full Text] [Related]  

  • 11. LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer.
    Song B; Li R; Zuo Z; Tan J; Liu L; Ding D; Lu Y; Hou D
    BMC Cancer; 2019 Apr; 19(1):297. PubMed ID: 30940124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases.
    Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Nozhat Z; Fanaei SA; Hedayati M; Azizi F
    Life Sci; 2019 Apr; 223():166-173. PubMed ID: 30890403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAZ promotes thyroid cancer progression by driving transcriptional reprogram and enhancing ERK1/2 activation.
    Zeng J; Zhang L; Huang L; Yu X; Han L; Zheng Y; Wang T; Zhang N; Yang M
    Cancer Lett; 2024 Oct; 602():217201. PubMed ID: 39197582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells.
    Llauradó M; Abal M; Castellví J; Cabrera S; Gil-Moreno A; Pérez-Benavente A; Colás E; Doll A; Dolcet X; Matias-Guiu X; Vazquez-Levin M; Reventós J; Ruiz A
    Int J Cancer; 2012 Apr; 130(7):1532-43. PubMed ID: 21520040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of BRAF V600E mutation in fine-needle aspiration fluid of papillary thyroid carcinoma by droplet digital PCR.
    Xu X; Ma X; Zhang X; Cao G; Tang Y; Deng X; Kang Z; Li M; Guan M
    Clin Chim Acta; 2019 Apr; 491():91-96. PubMed ID: 30682328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ETV5 overexpression contributes to tumor growth and progression of thyroid cancer through PIK3CA.
    Meng D; Li Z; Ma X; Wu L; Fu L; Qin G
    Life Sci; 2020 Jul; 253():117693. PubMed ID: 32325133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twist1 regulates the epithelial-mesenchymal transition via the NF-κB pathway in papillary thyroid carcinoma.
    Lv N; Shan Z; Gao Y; Guan H; Fan C; Wang H; Teng W
    Endocrine; 2016 Mar; 51(3):469-77. PubMed ID: 26289126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of SMOC2 expression in papillary thyroid carcinoma and its prognostic significance.
    Kim HS; Choi JH; Lee JY; Kang J; Myung JK; Kim WH; Jang BG
    Sci Rep; 2020 Mar; 10(1):4853. PubMed ID: 32184420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
    Bommarito A; Richiusa P; Carissimi E; Pizzolanti G; Rodolico V; Zito G; Criscimanna A; Di Blasi F; Pitrone M; Zerilli M; Amato MC; Spinelli G; Carina V; Modica G; Latteri MA; Galluzzo A; Giordano C
    Endocr Relat Cancer; 2011 Dec; 18(6):669-85. PubMed ID: 21903858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.
    Kim SW; Kim HK; Lee JI; Jang HW; Choe JH; Kim JH; Kim JS; Hur KY; Kim JH; Chung JH
    Endocr Res; 2013; 38(2):89-97. PubMed ID: 23544999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.